Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease

Zhenzhen Fang; Gang Shen; Yina Wang; Fuyan Hong; Xiumei Tang; Yongcheng Zeng; Ting Zhang; Huanyi Liu; Yanmei Li; Jinhong Wang; Jing Zhang; Anton Gao; Weiwei Qi; Xia Yang; Ti Zhou; Guoquan Gao

doi:10.1038/s41392-024-01781-9

. 2024 Mar 12;9:66. doi: 10.1038/s41392-024-01781-9

Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease

Zhenzhen Fang ^1,^#, Gang Shen ^1,^#, Yina Wang ^2,^#, Fuyan Hong ^1,^#, Xiumei Tang ³, Yongcheng Zeng ¹, Ting Zhang ⁴, Huanyi Liu ⁵, Yanmei Li ¹, Jinhong Wang ¹, Jing Zhang ¹, Anton Gao ⁶, Weiwei Qi ¹, Xia Yang ^1,^7,^✉, Ti Zhou ^1,^8,^✉, Guoquan Gao ^1,^9,^✉

PMCID: PMC10933339 PMID: 38472195

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and the development of non-alcoholic steatohepatitis (NASH) might cause irreversible hepatic damage. Hyperlipidemia (HLP) is the leading risk factor for NAFLD. This study aims to illuminate the causative contributor and potential mechanism of Kallistatin (KAL) mediating HLP to NAFLD. 221 healthy control and 253 HLP subjects, 62 healthy control and 44 NAFLD subjects were enrolled. The plasma KAL was significantly elevated in HLP subjects, especially in hypertriglyceridemia (HTG) subjects, and positively correlated with liver injury. Further, KAL levels of NAFLD patients were significantly up-regulated. KAL transgenic mice induced hepatic steatosis, inflammation, and fibrosis with time and accelerated inflammation development in high-fat diet (HFD) mice. In contrast, KAL knockout ameliorated steatosis and inflammation in high-fructose diet (HFruD) and methionine and choline-deficient (MCD) diet-induced NAFLD rats. Mechanistically, KAL induced hepatic steatosis and NASH by down-regulating adipose triglyceride lipase (ATGL) and comparative gene identification 58 (CGI-58) by LRP6/Gɑs/PKA/GSK3β pathway through down-regulating peroxisome proliferator-activated receptor γ (PPARγ) and up-regulating kruppel-like factor four (KLF4), respectively. CGI-58 is bound to NF-κB p65 in the cytoplasm, and diminishing CGI-58 facilitated p65 nuclear translocation and TNFα induction. Meanwhile, hepatic CGI-58-overexpress reverses NASH in KAL transgenic mice. Further, free fatty acids up-regulated KAL against thyroid hormone in hepatocytes. Moreover, Fenofibrate, one triglyceride-lowering drug, could reverse hepatic steatosis by down-regulating KAL. These results demonstrate that elevated KAL plays a crucial role in the development of HLP to NAFLD and may be served as a potential preventive and therapeutic target.

Subject terms: Metabolic disorders, Molecular medicine

Introduction

NAFLD also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a prevalent liver disease whose prevalence is as high as 25%,¹ characterized by excessive triglyceride (TG) deposition in hepatocytes, excluding significant alcohol consumption and other damaging factors.² A significant proportion of NAFLD patients in Asia are not obese; HLP, particularly HTG, was a significant risk factor for NAFLD;^3–5 Further, it is reported that non-obese NAFLD usually has higher plasma TG levels when compared with matched controls without NAFLD.⁶ However, the linking molecules and mechanisms between HLP and NAFLD are not fully understood.

NAFLD is a general term for a series of liver-related diseases, including hepatic steatosis, NASH, and liver cirrhosis.⁷ An imbalance between TG synthesis and clearance would cause accumulation of lipid droplet-like TG in the liver and induce hepatic steatosis.² Hepatic steatosis is often self-limited and reversible, but part of it can develop into NASH, which will cause irreversible damage to the liver, such as liver cirrhosis, liver failure, and hepatocellular carcinoma.⁸ In addition, NASH also causes non-liver-related adverse outcomes, such as cardiovascular disease and malignant tumors.⁹ However, there is currently no approved drug for NASH treatment.⁹ Knowledge of the pathogenesis of hepatic steatosis into NASH and fibrosis is still incomplete. Currently, chronic liver inflammation is knowledgeably considered to be the leading cause of NASH,¹⁰ and the NF-κB/TNFα signaling pathway is an important inflammatory signaling pathway involved in the development of chronic inflammation in NAFLD.¹¹

KAL, encoded by the SERPINA4, is a secreted protein mainly expressed in hepatocytes.¹² The previous studies, including ours’ showed that KAL levels in the peripheral blood of diabetic patients were significantly elevated^13,14 and positively correlated with TG.^14,15 Furthermore, we have reported that KAL could activate the nuclear factor κB (NF-κB) signaling pathway to cause inflammation in diabetic wound tissues.¹³ However, the relationship between lipid metabolic dysfunction, KAL, and NAFLD remains unclear. The Bioinformatic analysis of the plasma proteome also revealed several other significantly up-regulated proteins, IGHV4-4 (Immunoglobulin heavy variable 4-4), LAMB1 (Laminin subunit beta 1), and VNN1 (Vanin 1) (supplementary Fig. 1a). LAMB1 is a kind of extracellular matrix glycoprotein, which is mainly related to cell adhesion and migration; VNN1 is also a secreted protein mainly expressed in hepatocytes, however, it has been reported that knockout of VNN1 can promote the accumulation of TG in the liver under fasting state,¹⁶ suggesting that elevated VNN1 may not be a inducer of NAFLD. Thus, we choose SERPINA4 (KAL) for further study.

The present study aims to illuminate the role of KAL in the occurrence and development of NAFLD and the intermediary between HLP and NAFLD. Our results demonstrate for the first time that serum KAL is increased in NAFLD and acts as a potent initiator of hepatic steatosis and inflammation, promoting the progression of HFD mice from steatosis to NASH. Conversely, Serpina4^−/− alone had no effect on lipid metabolism and liver lesions, but ameliorated hepatic steatosis and inflammation in HFruD and MCD induced NAFLD rats. Mechanistically, KAL induced hepatic steatosis and NASH by down-regulating ATGL and CGI-58 by LRP6/Gɑs/PKA/GSK3β pathway. Consequently, diminishing CGI-58 activated NF-κB/TNFα signaling pathway. These data indicate that KAL is a critical regulatory molecule that mediates the occurrence and progression of NAFLD.

Results

The level of KAL is increased in HLP and NAFLD patients and positively correlated with TG

We reanalyzed a plasma proteome profiling in ProteomeXchange (PRIDE archive PXD011839, https://www.ebi.ac.uk/pride/archive/). The samples were divided into HTG and control groups based on TG levels (individuals with TG ≥ 1.7 mM are defined as HTG), excluding obese individuals and individuals over 60 years of age. With at least one valid value in the samples, we get a dataset of 593 protein groups. Using Student’s t-test to determine the significantly changed proteins with a p-value of 0.05. We found that KAL was significantly up-regulated in the HTG group (supplementary Fig. 1a).

To further investigate the potential association between KAL and HLP, we conducted a study involving 253 HLP and 221 age-matched healthy controls. The clinical and biochemical characteristics of the participants are summarized in supplementary Table 1. Our results indicated that plasma KAL levels were significantly higher in HLP subjects compared to healthy control and positively correlated with TG, free fatty acid (FFA), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and negatively correlated with high-density lipoprotein cholesterol (HDL-C) (Fig. 1a-b, supplementary Fig. 1b-e). Moreover, the plasma KAL levels in HTG subjects were even higher than those in the HLP without HTG group (Fig. 1c). We also found that the alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in HTG were higher than those in the HLP without HTG group and the healthy control group and positively correlated with KAL (Fig. 1d-e, supplementary Fig. 1f-g).

In addition, the serum KAL levels were higher in non-obese NAFLD patients than in matched healthy controls (Fig. 1f) and positively correlated with AST, ALT, and TG but not TC, LDL-C, and HDL-C (Fig. 1g-i, supplementary Fig. 1h-j, supplementary Table 2). Similarly, the KAL staining was increased in the liver of mild NAFLD patients (Fig. 1j). These findings suggested that elevated KAL levels are involved in the accumulation of TG and subsequent liver damage.

Elevated KAL induces hepatic steatosis and NASH in chow-diet mice and aggravates hepatic steatosis to NASH in HFD mice

To investigate the role of KAL in NAFLD, we conducted experiments on KAL-transgenic (KAL-Tg) mice. And the average serum KAL concentration of KAL-Tg mice was 2.6 μg/mL (Fig. 2a), which is of the same order of magnitude as that in the human HLP population (Fig. 1a, 2-10 μg/mL). We observed that KAL-Tg mice exhibited increased serum AST and ALT levels (Fig. 2b), indicating liver damage. Moreover, KAL-Tg mice exhibited slight hepatic lipid droplet deposition at 3 months and developed severe hepatic steatosis, disordered arrangement of hepatocytes, elevated hepatic TG and fatty acid levels, and increased liver weight at 6 months (Fig. 2c-g). It suggested that elevated KAL contributes to hepatic steatosis.

Fig. 2 — KAL induces hepatic steatosis and NASH in chow-diet mice and progresses hepatic steatosis to NASH in HFD mice. a The serum KAL concentration of KAL-Tg mice (n = 8). b The serum AST and ALT levels of 6-month-old mice (n = 5). c Oil red O staining and steatosis score of livers from 3-month-old mice (WT, n = 3; KAL-Tg, n = 4). Scale bar: 200 μm. d–g Weight, H&E (Scale bar: 100 μm) and Oil red O (Scale bar: 200 μm) staining, steatosis score, TG and fatty acid content of liver tissues from 6-month-old mice (n ≥ 8 per group). h–l Representative images, Oil red O and H&E staining, NAS, TNFα level of livers and serum TNFα in 10-month-old mice (n ≥ 5 per group). Scale bar: 100 μm. m–o Sirius staining and fibrosis scores, mRNA levels, and protein levels of genes related to inflammation and fibrosis in livers from 16-month-old mice (n ≥ 5 per group). Scale bar: 100 μm. p–r H&E and Sirius staining, NAS, fibrosis scores, mRNA levels and protein levels of genes related to inflammation and fibrosis of livers from mice fed an HFD for 28 weeks (n ≥ 4 per group). Scale bar: 100 μm. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001

To further investigate the effect of KAL on NASH, we found that the livers of 10-month-old KAL-Tg mice exhibited yellow and granular surfaces, and developed NASH with apparent inflammation, balloon-like degeneration of hepatocytes, and NAFLD activity score (NAS) greater than 5 (Fig. 2h-i, supplementary Fig. 2a-d). The expression and secretion of the inflammatory factor tumor necrosis factor α (TNFα) were also increased (Fig. 2j-l, supplementary Fig. 2e). Since the 10-month-old mice did not exhibit extensive fibrosis with collagen deposition (supplementary Fig. 2f), we continued to raise the mice for 16-month-old and found that 16-month-old KAL-Tg mice developed not only NASH (supplementary Fig. 2g–i) but also hepatic fibrosis with elevated α-smooth muscle actin (α-SMA) and collagen I (Fig. 2m-o).

Additionally, to clarify whether KAL speeds up the development of hepatic steatosis to NASH, the classic model of hepatic steatosis, HFD mice, was used. When we fed KAL-Tg mice and wild-type (WT) mice with HFD, KAL-Tg mice exhibited extensive inflammation, injury, and fibrosis along with aggravated hepatic steatosis (Fig. 2p, supplementary Fig. 2j-m), and the expression of TNFα, interleukin-6 (IL-6), α-SMA, and collagen I was also increased (Fig. 2q-r, supplementary Fig. 2n). Our findings suggest that elevated KAL contributes to the progression of simple hepatic steatosis to NASH in HFD mice.

Knockout of KAL ameliorates hepatic steatosis and inflammation in NAFLD rats

As previously mentioned, KAL is a secreted protein. To elucidate the role of KAL in NAFLD, we generated KAL gene knockout (Serpina4^−/−) rats and fed them with a HFruD for 16 weeks to induce an HTG non-obese NAFLD model (Fig. 3a), and found that the expression of KAL in the liver was higher in HFruD rats; Serpina4^−/− rats showed a significant improvement in hepatic steatosis in HFruD rats (Fig. 3b-c). Furthermore, fed Serpina4^−/− rats with a MCD diet for 4 weeks to induce hepatic steatosis and 10 weeks to NASH, respectively. We observed that the expression of KAL in the liver was also higher in MCD diet-induced NAFLD rats (Fig. 3d); Serpina4^−/− rats showed a significant improvement in hepatic steatosis, inflammation, and collagen fiber deposition in MCD-induced NAFLD rats (Fig. 3e-f). Additionally, Serpina4^−/− down-regulated the expression of TNFα, α-SMA and Collagen I in the liver tissue of MCD-induced NAFLD rats (Fig. 3g-h, supplementary Fig. 2o). These loss-of-function experiments provide evidence that high levels of KAL contribute to NAFLD.

Fig. 3 — KAL knockout improves hepatic steatosis, inflammatory infiltration and fibrosis of NAFLD rats. a The serum TG of rats fed with HFruD for 16 weeks. b, c mRNA levels of *Serpina4*, Oil red O staining and steatosis score of livers from the rats fed with HFruD for 16 weeks. d mRNA levels of *Serpina4* in the livers from rats fed with MCD. e Oil red O staining and steatosis score of livers from the rats fed with MCD for 4 weeks. f Oil red O staining and steatosis score, H&E staining and NAS, Sirius staining and fibrosis scores of livers from the rats fed with MCD for 10 weeks. g The mRNA levels of *Tnf*, *Acta2* and *Col1a1* in the livers of rats fed with MCD for 10 weeks. h Immunoblot of TNFα, α-SMA, and Collagen I in the liver tissues from rats fed with MCD for 10 weeks, the black arrow represents the destination blots. Scale bar for Oil red O staining: 500 μm, for H&E staining and Sirius staining: 200 μm. Data are expressed as mean ± SD of no less than 4 rats per group. *p < 0.05, **p < 0.01, ***p < 0.001

KAL causes hepatic steatosis by down-regulating both CGI-58 and ATGL, and inflammation mainly by CGI-58

Our RNAseq result of primary hepatocytes from 6-month-old WT and KAL-Tg mice indicated the downregulation of ATGL (encoded by the Pnpla2) and CGI-58 (encoded by the Abhd5) (supplementary Fig. 3a-b) (GSA dataset CRA014927), which are closed related with NAFLD. Hepatic ectopic deposition of lipid droplet-like triglycerides is influenced by several factors, including increased uptake and de novo synthesis of FFA, reduced β-oxidation of FFA, reduced TG hydrolysis, and extracellular transport through VLDL.² Our study revealed that KAL did not increase FFA synthesis and uptake, had no effect on the FFA β-oxidation and the critical molecules of VLDL synthesis (supplementary Fig. 3c-d), nor did it alter the Akt signaling pathway or hepatic glucose transporter (supplementary Fig. 3e). Consistent with RNAseq results, the expressions of ATGL, a critical enzyme for TG hydrolysis, and its co-activator CGI-58 were significantly decreased by KAL (Fig. 4a). Moreover, ATGL and CGI-58 were down-regulated in primary hepatocytes treated with Ad-KAL or primary hepatocytes from KAL-Tg mice (Fig. 4b-c, supplementary Fig. 3f-g). Overexpression of ATGL and/or CGI-58 could reduce the lipid droplet induced by KAL in hepatocytes (Fig. 4d). Similarly, decreased ATGL and CGI-58 expression in liver tissue was observed in MCD and HFruD-induced NAFLD rats, which was effectively rescued by Serpina4^−/− (Fig. 4e-f). Therefore, it is suggested that KAL inhibited hepatic TG hydrolysis by suppressing CGI-58 and ATGL, leading to hepatic steatosis.

Further, we observed that the expression of ATGL, but not CGI-58, had begun to decline in the liver tissues of 3-month-old KAL-Tg mice (Fig. 4g, supplementary Fig. 3h). In addition, we analyzed a human NAFLD data set (GSE89632) and found that CGI-58 expression was decreased in liver tissues of patients with hepatic steatosis and NASH and was significantly negatively correlated with KAL (Fig. 4h-i). Studies have shown that deficiency of liver ATGL causes hepatic steatosis but not NASH or fibrosis,¹⁷ whereas hepatic CGI-58 deficient mice exhibit pronounced hepatic steatosis and later develop NASH and liver fibrosis, accompanied by increases in TNFα and α-SMA.¹⁸ Individuals with CGI-58 loss-of-function mutations typically experience severe hepatic steatosis, NASH, and cirrhosis.¹⁹ Our results showed that KAL up-regulated the expression and secretion of TNFα in primary hepatocytes (Fig. 4j-l), which could be inhibited by CGI-58 but not ATGL (Fig. 4m–o). Furthermore, KAL did not affect the expression of CGI-58 in macrophages (Fig. 4p-q). Thus, our findings suggest that KAL induces the expression of TNFα by downregulating CGI-58 in hepatocytes and leading to inflammation through an ATGL-independent mechanism.

KAL induces nuclear translocation of NF-κB p65 by reducing its binding to CGI-58 in hepatocytes

In relation to the upregulation of TNFα expression resulting from the reduction of CGI-58, a question was raised regarding the mechanism involved. Our investigation first focused on NF-κB, a crucial inflammatory signaling pathway implicated in chronic inflammation associated with NAFLD¹¹ and a known inducer of TNFα transcription.²⁰ Previous research has indicated that the activation of the NF-κB signaling pathway by KAL results in inflammation in diabetic wound tissues.¹³ However, whether reducing CGI-58 would activate the NF-κB signaling pathway and lead to the upregulation of TNFα induced by KAL is unknown.

It is essential for NF-κB p65 to translocate into the nucleus to induce gene expression.²¹ Our findings indicate a significant increase in the nuclear translocation of NF-κB p65 in liver tissues of KAL-Tg mice and primary hepatocytes treated with Ad-KAL (Fig. 5a-b, supplementary Fig. 4a-c). Knocking down CGI-58 led to a notable increase in the nuclear translocation of NF-κB p65, along with the expression of TNFα and matrix metalloproteinase (MMP9), a well-established target of NF-κB, in primary hepatocytes (Fig. 5c-f). Furthermore, overexpressing CGI-58 could block the nuclear translocation of NF-κB p65 induced by KAL (Fig. 5g). Taken together, our results demonstrate that reducing CGI-58 leads to the activation of the NF-κB/TNFα signaling pathway.

Fig. 5 — KAL induces nuclear translocation of NF-κB p65 by reducing its binding to CGI-58 in hepatocytes. a NF-κB p65 levels in cytosolic (Cyto.) and nuclear (Nuc.) extracts in liver tissues from 10-month-old mice. b NF-κB p65 (green) immunostaining in primary hepatocytes treated with Ad-KAL for 48 h. Scale bar: 100 μm. **c–f** Representative immunoblot and quantification of NF-κB p65 in nuclear extracts (c), mRNA levels of TNFα (d), representative immunoblot and quantification of TNFα (e), and supernatant TNFα levels (f) in hepatocytes treated with si-*Abhd5* for 48 h. g Representative immunoblot and quantification of NF-κB p65 in nuclear extracts of primary hepatocytes transfected with KAL and CGI-58 plasmid for 48 h. h NF-κB p65 (green) and CGI-58 (red) immunostaining in primary hepatocytes. Images were acquired under a laser-scanning confocal microscope. Scale bar: 25 μm. i NF-κB p65 and CGI-58 levels in Cyto and Nuc extracts of primary hepatocytes. j NF-κB p65 immunoblotting after immunoprecipitation (IP) for CGI-58 in primary hepatocytes, IP for IgG as the negative control. k The co-IP blot and quantification of CGI-58 and NF-κB p65 in primary hepatocytes treated with Ad-KAL for 48 h, IP for IgG as the negative control. l, m Oil red O staining, H&E staining and nuclear NF-κB p65 levels in liver tissues of hepatic CGI-58-overexpressing KAL-Tg mice (KAL + CGI-58^LSL/+:Cre), the black arrow represents the destination blots. Scale bar for Oil red O staining: 200 μm, for H&E staining: 100 μm. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01

To further explore how CGI-58 regulates the nuclear translocation of NF-κB p65, we performed immunofluorescence staining with NF-κB p65 and CGI-58 and found their co-localization in the cytoplasm; CGI-58 was only localized in the cytoplasm (Fig. 5h, i, supplementary Fig. 4d). Immunoprecipitation (IP) for CGI-58 in hepatocyte cytoplasm fractions identified an interaction between NF-κB p65 and p-NF-κB p65 with CGI-58, which was impaired by Ad-KAL or si-Abhd5 (Fig. 5j, k, supplementary Fig. 4e). We also performed co-IP to identify the NF-κB subunits that mediate NF-κB activation in the absence of CGI-58 and found that the p65-p50 interactions were potentiated by reduced CGI-58 in hepatocytes (Supplementary Fig. 4f). Thus, our findings suggest that KAL down-regulates CGI-58, which interacts with NF-κB p65 and sequesters p65 in the cytoplasm, subsequently releasing p65 to facilitate its nuclear translocation.

To further investigate the key role of CGI-58 in hepatocytes regarding hepatic steatosis and inflammation induced by KAL, we constructed hepatic-specific CGI-58-transgenic mice (CGI-58^LSL/+:Cre), which were bred with KAL-Tg mice to construct the hepatic CGI-58-overexpressing KAL-Tg mouse model (KAL + CGI-58^LSL/+:Cre). Our results indicate that hepatic CGI-58 overexpression significantly reversed hepatic steatosis, inflammation, and the content of nuclear NF-κB p65 in KAL-Tg mice (Fig. 5l, m). It suggests that KAL induces NASH primarily through CGI-58.

KAL down-regulates ATGL and CGI-58 by inhibiting PPARγ or inducing KLF4, respectively

The underlying mechanism by which KAL down-regulated ATGL and CGI-58 requires further clarification. As shown in Fig. 4c and supplementary Fig. 3g, KAL inhibited the transcription of ATGL and CGI-58 in hepatocytes. It was reported that PPARγ could directly bind to the promoter of ATGL and enhance its transcription;²² Bioinformatics prediction indicated that PPARγ may also bind to the CGI-58 promoter (supplementary Fig. 5a); Moreover, PPARγ is closely related to NAFLD.²³ However, in hepatocytes, PPARγ promoted the expression of ATGL but not CGI-58 (Fig. 6a). KAL suppressed the expression of PPARγ in liver tissues, and Serpina4^-/- significantly improved the downregulation of PPARγ in MCD-induced NAFLD rats (Fig. 6b, supplementary Fig. 5b). Overexpression of PPARγ could block the downregulation of ATGL induced by KAL in hepatocytes (Fig. 6c). Therefore, it is suggested that KAL down-regulated ATGL by inhibiting PPARγ.

Fig. 6 — KAL down-regulates ATGL and CGI-58 by inhibiting PPARγ and up-regulating KLF4, respectively. a PPARγ, ATGL and CGI-58 levels in primary hepatocytes transfected with PPARγ plasmid for 48 h. b PPARγ levels in liver tissues of 6-month-old mice. c Representative immunoblot and quantification of ATGL in primary hepatocytes transfected with Ad-KAL and PPARγ plasmid for 48 h. d, e Representative immunoblot and quantification of protein levels, and mRNA levels of KLF4 in primary hepatocytes transfected with Ad-KAL for 48 h. f Representative immunoblot and quantification of KLF4 and Sp1 in liver tissues of 16-month-old mice. g, h Representative immunoblot and quantification of CGI-58, mRNA levels of CGI-58 in primary hepatocytes transfected with KLF4 plasmid for 24 h. i Luciferase reporter assays of primary hepatocytes transfected with CGI-58 promoter reporters and KLF4 plasmids for 24 h. j Representative immunoblot and quantification of CGI-58 in primary hepatocytes treated with Ad-KAL and si-KLF4 for 48 h. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001

Furthermore, we found that the CGI-58 promotor contains a G/C-rich element. The classical transcription factors that could bind to this element were KLF4 and Sp1.²⁴ KAL was found to up-regulate KLF4 but not Sp1 in hepatocytes (Fig. 6d-e); KLF4, not Sp1, was significantly elevated in liver tissues of KAL-Tg mice (Fig. 6f). Furthermore, KLF4 inhibited the expression of CGI-58 and the activity of its promoter in hepatocytes (Fig. 6g-i). Silencing of KLF4 reversed the downregulation of CGI-58 induced by KAL in hepatocytes (Fig. 6j). Hence, it is suggested that KAL down-regulated CGI-58 by inducing KLF4.

KAL regulates KLF4 and PPARγ by LRP6/Gαs/PKA/GSK3β signals

KAL is a well-known suppressor of the GSK3β/β-catenin signaling pathway by binding with low-density lipoprotein receptor-related protein 6 (LRP6).²⁵ Surprisingly, our findings suggest that KAL does not affect the expression of Wnt ligands, the composition of DVL/GSK3β/β-catenin, and β-catenin activity, but significantly down-regulates the phosphorylation of both LRP6 and glycogen synthase kinase-3 (GSK3β) markedly (Fig. 7a, supplementary Fig. 6a-b). Hepatocytes express various G-protein-coupled receptors (GPCRs) such as the glucagon receptor and thyrotropin-releasing hormone receptor;²⁶ LRP6, a coreceptor of GPCRs, is required for the activation of protein kinase A (PKA) under the stimulation of different GPCR ligands through the membrane G protein α(s) subunit (Gαs);²⁷ What is more, PKA was the classical kinases that could phosphorylate GSK3β and leading to its inactivation.²⁸ Our results indicate that KAL can bind to LRP6 in hepatocytes, and this binding is enhanced upon KAL overexpression (Fig. 7b); KAL also disrupts the localization of Gαs to the plasma membrane (supplementary Fig. 6c) and inhibits the phosphorylation of PKA in hepatocytes, treatment with the PKA agonist Dibutyryl-cAMP (db-cAMP) blocks the downregulation of p-GSK3β induced by KAL (Fig. 7c, supplementary Fig. 6d); Moreover, the phosphorylation of LRP6, PKA, and GSK3β is reduced in the livers of KAL-Tg mice (Fig. 7d, supplementary Fig. 6e). Therefore, we propose that KAL may inhibit LRP6/Gαs/PKA/GSK3β signaling.

Fig. 7 — KAL regulates KLF4 and PPARγ by activating GSK3β. **a–c** Protein levels of non-p-β-catenin, p-GSK3β, p-LRP6 (a), p-PKA (c), and the IP blot of KAL and LRP6 (b) in hepatocytes treated with Ad-KAL for 48 h. d Protein levels of p-LRP6, p-PKA, p-GSK3β in liver tissues of 16-month-old mice. e, f Representative immunoblot and quantification of protein levels, mRNA levels of ATGL and PPARγ in hepatocytes treated with Ad-KAL and LiCl (20 mM) for 48 h. g, h Protein levels and mRNA levels of CGI-58 in hepatocytes treated with LiCl (20 mM) for 48 h. i Protein level of CGI-58 in hepatocytes treated with LiCl (20 mM) and si-β-catenin for 48 h. j, k Representative immunoblot and quantification of protein levels, mRNA levels of CGI-58 and KLF4 in hepatocytes treated with Ad-KAL and LiCl (20 mM) for 48 h. l Representative immunoblot and quantification of KLF4 in nuclear extracts of hepatocytes treated with Ad-KAL and LiCl (20 mM) for 48 h. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001

It has been reported that PPARγ is downstream of GSK3β.²⁹ Inhibition of GSK3β with lithium chloride (LiCl) can block the downregulation of PPARγ and ATGL induced by KAL (Fig. 7e, f). Additionally, LiCl induces the expression of CGI-58, which is not improved by β-catenin interference (Fig. 7g–i). Furthermore, LiCl significantly disrupts the regulatory effects of KAL on CGI-58 and KLF4, as well as the nuclear translocation of KLF4 (Fig. 7j–l). Therefore, we suggest that KAL regulates KLF4 and PPARγ by activating GSK3β.

High FFA reverses the downregulation of KAL induced by T3, and fenofibrate down-regulates KAL in hepatocytes

The regulation of KAL gene expression remains poorly understood, leading to the question of how KAL is up-regulated. It has been reported that HTG is accompanied by higher levels of FFA, a product of lipid metabolic dysfunction,³⁰ and NAFLD patients had significantly higher serum FFA levels than controls.³¹ FFA examined in our HLP subjects was positively correlated with plasma KAL levels (supplementary Fig. 1e). Our findings indicate that high levels of FFA alone do not affect KAL expression (Fig. 8a). A previous study has shown that Serpina3c, a member of the same family as KAL, is negatively regulated by thyroid hormone T3: T3 binds to thyroid hormone receptor (TR), then liganded TR recruits nuclear receptor corepressor and represses the expression of Serpina3c.³² Our results show that T3 also down-regulates KAL expression in hepatocytes (Fig. 8b). Additionally, T3 binding to TR is significantly inhibited when plasma and cell FFA are increased.³³ Furthermore, our results demonstrate that high FFA can counteract the down-regulation of KAL expression and secretion induced by T3 in hepatocytes (Fig. 8c-h). Most T3 is produced from the conversion of thyroid hormone T4 in peripheral tissues, especially the liver and kidney.³⁴ Thus, these results suggest that high FFA, a product of lipid metabolic dysfunction, can elevate KAL and indicate that KAL is a linker between HLP and NAFLD.

Fig. 8 — High FFA reverses the downregulation of KAL induced by T3 and Fenofibrate down-regulates KAL in hepatocytes. a Protein levels of KAL in L-02 cells treated with OP (250 μM Oleic acid add 250 μM Palmitic acid) or BSA (Bovine serum albumin) for 24 h. b Protein levels of KAL in L-02 cells treated with T3 (25 nM) for 24 h. c–f Representative immunoblot and quantification of KAL, mRNA levels of KAL, and supernatant KAL levels in L-02 cells treated with T3 (25 nM) with/without OP for 24 h. g–h mRNA levels of KAL, supernatant KAL levels in MIHA cells treated with T3 (25 nM) with/without OP for 24 h. i–k Representative immunoblot of KAL, ATGL, CGI-58 in L-02 cells treated with Metformin (Met), Berberine (BBR), or Fenofibrate (Feno). l Supernatant KAL levels in L-02 cells treated with Feno. m–p Oil red O staining, serum TG level, steatosis score, and the mRNA level of KAL in livers from the rats fed with HFruD for 12 weeks, followed by the treatment of 100 mg/kg Feno and HFruD for 4 weeks. Scale bar: 500 μm. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001

We also investigated whether compound drugs with improved hepatic steatosis and/or lipid-lowering effects, such as Metformin, Berberine, and Fenofibrate, could decrease KAL expression. Our findings show that only Fenofibrate, a kind of drug for severe HTG, but not Metformin and Berberine, can down-regulate the expression and secretion of KAL and subsequently improve the expression of ATGL and CGI-58 in hepatocytes (Fig. 8i–l). Further, intragastric administration of 100 mg/kg Fenofibrate daily reversed serum TG level, hepatic steatosis, and upregulation of KAL in the livers of HfruD rats (Fig. 8m–p). These results suggest that triglyceride-lowering drugs may benefit NAFLD by decreasing KAL.

Discussion

The transition from hepatic steatosis to NASH plays a crucial role in the progression of NAFLD to irreversible liver damage.⁸ However, the key molecules and signaling pathways involved in this process are not yet fully understood. NAFLD is more prevalent in individuals with HTG than those with HTC (High total cholesterol);³ Our data showed that the proportion of subjects with elevated KAL was also higher in the HTG population than in the HTC population (Fig. 1c). Non-obese NAFLD usually has higher TG levels when compared with matched controls.⁶ Our study focused on the non-obese NAFLD, and found that KAL was significantly elevated in HTG subjects and NAFLD patients and positively correlated with TG; Additionally, feeding with HFruD is the classical animal model of HTG, and KAL deficiency could significantly reverse the hepatic steatosis of HFruD rats; FFA, the consequent product of lipid metabolic dysfunction, cooperated with T3 and up-regulated KAL in hepatocytes. Therefore, we believe that lipid metabolic dysfunction is the cause of elevated KAL in HLP and NAFLD patients and suggests that KAL may be the causative contributor that mediates HLP to NAFLD.

The NAFLD patients included in this project were mild, and hepatocyte necrosis had not yet occurred (Fig. 1), enabling us to examine the change and role of KAL in the early stages of the disease. It has been reported that KAL was lower in the serum of liver cirrhosis patients.³⁵ As mentioned above, KAL is mainly produced by hepatocytes,¹² so KAL levels are expected to decrease in the late stage of liver cirrhosis when hepatocytes are necrotic. Our results indicate that elevated KAL could initiate liver injury and induce irreversible NASH, which in turn leads to a decline of KAL.

Mechanistically, KAL down-regulated the expression of ATGL and CGI-58, which play critical roles in TG hydrolysis and hepatic steatosis.^36,37 Furthermore, KAL inhibited the transcription of ATGL by down-regulating PPARγ. Previous clinical trials have shown that Pioglitazone, a PPARγ agonist, can improve hepatic steatosis in NAFLD patients but does not affect NASH or liver fibrosis.³⁸ Our findings suggest that PPARγ may only regulate the transcription of ATGL but not CGI-58, which may explain why Pioglitazone is ineffective in treating NASH and liver fibrosis.

Previous studies on CGI-58 transcription regulation have mainly focused on Qinchuan cattle.^39,40 Our study identified KLF4 as a transcription suppressor of CGI-58 and demonstrated that KAL down-regulates CGI-58 by elevating KLF4 for the first time. The importance of CGI-58 in hepatic steatosis, NASH, and fibrosis has been clarified through studies on CGI-58 knockout mice and the CGI-58 mutation population.^18,41 Furthermore, the deficiency of liver ATGL caused hepatic steatosis, but not NASH or fibrosis,^17,42 suggesting that CGI-58 could regulate hepatic inflammation and fibrosis through an ATGL-independent mechanism.⁴³ However, the mechanism of CGI-58 in regulating NASH and fibrosis is still unclear. TNFα was increased in the liver of hepatocyte-specific CGI-58 knockout mice,^18,44 similar to KAL-Tg mice. In addition, it was reported that CGI-58 could suppress the nuclear translocation of NF-κB p65 in tumor-associated macrophages.⁴⁵ We clarified for the first time that CGI-58 could bind NF-κB p65 and sequester it in the cytoplasm. Diminishing CGI-58 induced by KAL released p65 to facilitate its nuclear translocation and subsequently induced the expression of TNFα. At the same time, it is reported that phosphorylation of NF-κB p65 can enhance its transcriptional activity and promote its nuclear translocation,⁴⁶ and our results showed that CGI-58 could also bind to p-NF-κB p65 in the cytoplasm (Fig. 5j). Therefore, we speculate that even if the NF-κB p65 was phosphorylated, CGI-58 could still sequester it in the cytoplasm, which indicates that CGI-58 is a novel endogenous inhibitor of the NF-κB signaling pathway in hepatocytes.

Although Kupffer cells (macrophages) are known to promote an inflammatory response in the development of NASH, it has also been reported that injured hepatocytes produce pro-inflammatory cytokines and chemokines.⁴⁷ Since hepatocyte-specific CGI-58 knockout mice exhibited inflammation and fibrosis in the liver, our experiment shows that KAL specifically down-regulates CGI-58 and induces TNFα in hepatocytes but not macrophages, and hepatocyte-specific CGI-58-overexpression could improve the hepatic steatosis and inflammation of KAL-Tg mice. Thus, KAL primarily targets hepatocytes and plays a direct pro-inflammatory role.

Previous studies have reported that KAL can inhibit inflammatory responses in hypertensive rats, mice with multifactorial sepsis, and endotoxemia,^48–50 suggesting that KAL has anti-inflammatory effects that contradict our findings. These studies were conducted in acute inflammation models induced by lipopolysaccharides (LPS), whereas NASH is a chronic inflammatory condition. Moreover, KAL has a dual role in angiogenesis, apoptosis, oxidative stress, and inflammation.⁵¹ At physiological concentrations, KAL is not harmful, but either too low or too high concentrations can be damaging. For instance, elevated KAL levels have been found in patients with type I and type II diabetes, and our recent study showed that elevated KAL can activate the NF-κB signaling pathway to cause chronic inflammation in diabetic wound tissues.^13,14 Similarly, our present study shows that elevated KAL leads to NASH by down-regulating CGI58, reflecting a pro-inflammatory effect. The study adds to our understanding of the dual role of KAL in physiological and pathological conditions.

Our study also investigated the potential therapeutic effects of drugs on KAL levels in NAFLD. Metformin and Berberine have demonstrated a broad spectrum of pharmacological effects and potential therapeutic effects on NAFLD; Fenofibrate is a kind of drug for treating HLP, especially severe HTG, and can reduce the content of FFA while reducing TG.⁵² We found that Fenofibrate, but not Metformin and Berberine, down-regulates KAL levels. Metformin treatment is effective for diabetic NAFLD patients;⁵³ However, a meta-analysis showed that metformin was not associated with liver histologic improvement in NASH patients without diabetes.⁵⁴ Berberine improves hepatic steatosis but has no effect on NASH;⁵⁵ moreover, it is reported that LDL-lowering drugs Statins do not respond well to NASH.³⁸ Previous clinical trials of Fenofibrate on NAFLD have yielded mixed results, with some studies reporting improvements in TG, AST, ALT, hepatic steatosis, inflammation and liver stiffness, while others found no significant benefits.^56–60 Our findings suggest that drugs with TG-lowering or FFA-lowering effects may effectively treat NAFLD/NASH by down-regulating KAL levels. Therefore, Fenofibrate may be a promising treatment option for NAFLD patients with elevated KAL levels, yet clinical trials are needed to confirm its efficacy.

In summary, our study suggests that elevated KAL levels contribute to the occurrence and development of NAFLD by targeting the CGI-58/NF-κB/TNFα pathway (Fig. 9). This finding enhances our understanding of the pathophysiology of NAFLD and highlights KAL as a potential therapeutic target for NAFLD treatment. Thus, targeting KAL in the early stages of NAFLD may represent a promising therapeutic strategy.

Fig. 9 — A schematic model of the contributor and potential mechanism of KAL in the occurrence and development of NAFLD. KAL is increased in HTG subjects and NAFLD patients. FFA, the consequent product of HTG, up-regulates KAL in hepatocytes. Elevated KAL induced hepatic steatosis and NASH by down-regulating ATGL and CGI-58 by LRP6/PKA/GSK3β pathway. Consequently, diminishing CGI-58 activated NF-κB/TNFα signaling pathway. Fenofibrate may benefit NAFLD by decreasing KAL

Materials and methods

Ethics statements

This study collected blood samples from human subjects. All participants provided written informed consent. This study was approved by the Medical Ethics Committees of Zhongshan Medical School, Sun Yat-Sen University (Approval number ZZSOM-MEC-2022-001).

The animal experimental process has been reviewed and approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (SYSU-IACUC-2022-B0016).

Experimental design of human subjects

We enrolled 221 healthy control and 253 HLP subjects in the Clinical Laboratory of Guangzhou First People’s Hospital and enrolled 115 participants in the Physical Examination Centre of the Third Affiliated Hospital of Sun Yat-Sen University, which included 53 NAFLD patients and 62 age-matched healthy control. According to the color ultrasound, the diagnosis of NAFLD was that more than 5% of hepatic cells appeared steatosis was considered to be NAFLD. Exclusion criteria included obesity, viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration or other liver diseases, and alcoholic fatty liver disease (daily alcohol consumption of more than 30 g for men and 20 g for women).

Experimental design of animals

KAL knockout (Serpina4^−/−) Sprague-Dawley rat strain was constructed by Guangzhou Saiye Biotechnology Co., Ltd., using CRISPR/Cas9 technology; Five exons have been identified in the rat Serpina4 gene, with the ATG start codon in exon 2 and TAG stop codon in exon 5, and Exon 2 to exon 3 was selected as target sites (supplementary Fig. 7a). The KAL transgenic (KAL-Tg) C57BL/6 mouse strain was provided as a gift from Dr. Jianxing Ma (University of Oklahoma Health Sciences Center).⁶¹ KAL-Tg mice and litter wild-type mice were raised at different ages to confirm the change in the liver. In some experiments, the 6-week-old KAL-Tg mice and litter wild-type mice were fed a 60% fat calories HFD (Research Diets) for 28 weeks; and 8-week-old Serpina4^−/− rats and age-matched wild-type rats fed with 70% HFruD (ReadyDietech) for 16 weeks, MCD (Dyets) for four weeks or ten weeks. The serum contents of AST, ALT, TG, TC, LDL-C, and HDL-C were analyzed by the Hitachi Biochemistry Analyzer. In addition, the TG and fatty acid content of liver tissues were quantified by commercial kits purchased from BioAssay Systems (ETGA-200 and EFFA-100, USA).

CGI-58-transgenic mice were constructed by Shanghai Model Organisms, using CRISPR/Cas9 technology; The CAG-LSL-ABHD5-WPRE-polyA expression frame was inserted at the Rosa26 gene locus through homologous recombination (supplementary Fig. 7b-c). Then breeding them with Alb-cre mice to obtain liver-specific overexpression CGI-58 mice, which were bred with KAL-Tg mice to construct the hepatic CGI-58-overexpressing KAL-Tg mouse model (KAL + CGI-58^LSL/+:Cre) for experiments.

All animals were fed in the Specific-pathogen-free (SPF) environment of the Experimental Animal Centre of Zhongshan School of Medicine, Sun Yat-Sen University. The use and handling of all animals strictly follow Sun Yat-Sen University’s experimental animal use guidelines.

Cell-culture experiments

Primary hepatocytes were isolated and purified from the liver tissue of mice. Briefly, insert the catheter into the portal vein, perfuse the liver with D-Hank’s buffer (PYG0075, Boster, China) to flush the liver of red blood cells, and cut the inferior vena cave to release pressure in the liver. Then, perfuse the liver with digestion buffer (0.4 mg/mL collagenase IV, C5138, Sigma, USA); the digested livers were removed and dispersed in DMED medium with 10% fetal bovine serum. The cells were cultured in Willian’s E medium (Gibco) with 10% FBS, 2% hepatocyte maintenance culture supplement (Gibco), and 1% streptomycin/ penicillin. Glycogen Periodic Acid Schiff (PAS) staining (BP-DL036, SenBeiJia Biological Technology, Nanjing, China) and immunofluorescence of CK-18 (AF1285, Beyotime) were used to identify mouse primary hepatocytes (supplementary Fig. 8).

Histological analyses

Frozen sections of the liver were stained with Oil red O to determine the degree of steatosis. Paraffin-embedded tissue sections were stained with Hematoxylin-eosin (HE) to determine the tissue morphology and inflammation and stained with Sirius red to determine the fibrosis. All images were captured using an automatic digital slide scanning system (AxioScan.Z1, Zeiss, DE). NAS was scored using the NASH Clinical Research Network Histologic Scoring System. NAS system and liver fibrosis score were used for semi-quantitative analysis of the main histopathological characteristics of NAFLD.^62,63 The NAS was an unweighted scoring system based on levels of steatosis(0–3), lobular inflammation(0–3), and hepatocyte ballooning(0–2). The criteria to diagnose NASH is a NAS score of 5 or greater. The evaluation criteria are detailed in supplementary Table 3.

Enzyme-linked immuno sorbent assay (ELISA) specific for KAL

The concentration of plasma and serum KAL were quantified by commercial ELISA kits purchased from R&D Systems (DY1669).

Immunoprecipitation, isolation of nuclear fractions and western blot

Immunoprecipitation was performed to detect protein complex formation. Wash the cells with cold PBS and lyse with RIPA buffer (P0013D, Beyotime, China). The lysate was incubated with a primary antibody overnight. Then, Protein A/G PLUS Agarose (sc-2003, Santa Cruz) was added and further rotated for 6 h. Finally, the Agarose-antibodies-protein complex was washed with RIPA buffer three times and analyzed by western blot. Nuclear fraction was performed by Nuclear and Cytoplasmic Protein Extraction Kit (P0027, Beyotime, China) and analyzed by western blot. Antibody information is indicated in Supplementary Table 4. The results were quantified by the National Institutes of Health [NIH] ImageJ 1.34.

Plasmids, siRNA, and transfection

Adenovirus overexpressing KAL (Ad-KAL) and adenovirus overexpressing red fluorescent protein (Ad-RFP) were purchased from Obio Technology Corp Ltd (Shanghai, China). Plasmids encoding PPARγ, ATGL, CGI-58, and KLF4 were purchased from MiaoLing Plasmid Sharing Platform (Wuhan, China). Transfection of plasmids was performed at 70%-80% confluency using Lipofectamine 3000 (L3000015, Gibco, USA) according to the manufacturer’s instructions. CGI-58 siRNA and KLF4 siRNA were purchased from RiboBio (Guangzhou, China); the Interference sequence is listed in supplementary Table 5. Transfection of siRNA was performed using Lipofectamine RNAiMAX (13778150, Gibco, USA).

RNA isolation and real-time quantitative polymerase chain reaction (RT-qPCR)

The isolation and reverse transcription of RNA were performed by commercial kits purchased from EZBioscience (EZB-RN001-plus for tissues, B0003C for cells). RT-qPCR was performed with SYBR® Green I (Takara, China) by a Real-time fluorescent quantitative PCR system (Bio-rad, USA). The PCR primer sequences are listed in supplementary Table 5.

Luciferase reporter assay

Luciferase assay was performed using the Dual-Luciferase Reporter Assay Kit (E1910, Promega, USA). We defined the CGI-58 promoter region spanning nucleotides −1000 to +224 as a full-length promoter, which was cloned into the KpnI/HindIII sites of pGL3-basic luciferase reporter plasmid to generate CGI-58 luciferase reporters.

Statistical analysis

Each experiment was replicated with three or more separate samples. SPSS 21.0 was used for statistical analysis, and GraphPad Prism 7 was used for graphing. Continuous quantitative data conforming to the normal distribution were revealed as mean ± standard deviation (mean ± SD), the difference between the two groups was made by Student’s t test or paired t test, and p < 0.05 was considered statistically significant. The values for N and the specific statistical test performed for each experiment were included in the figure legends.

Supplementary information

supplementary figures and tables^{(3.1MB, docx)}

Unmodified gels^{(2.1MB, pdf)}

Acknowledgements

This study was supported by The National Natural Science Foundation of China (Grants 82070888, 82100917, 82070882, 82273116, and 82203661); National Key R&D Program of China (Grant 2018YFA0800403); Guangdong Special Support Program for Young Top Scientist (Grant 201629046); Guangdong Natural Science Fund (Grant 2021A1515010434, 2022A1515012423, 2022A1515012513 and 2023A1515010316); Key Sci-Tech Research Project of Guangzhou Municipality (202201010820); China Postdoctoral Science Foundation (Grant 2021M703679); Guangzhou Key Laboratory for Metabolic Diseases(202102100004); 2019 Milstein Medical Asian American Partnership Foundation Research Project Award in Translational Medicine.

Author contributions

G.Q.G., T.Z., X.Y. designed research; Z.Z.F. and G.S. performed the animal experiments and liver histological analyses; Z.Z.F., F.Y.H. and Y.C.Z. performed the cell experiments to investigate the mechanism; Y.N.W., X.M.T., T.Z. and H.Y.L. recruited patients and collected clinical data and biological samples; Z.Z.F., Y.M.L., J.H.W., J.Z., A.T.G. and W.W.Q. analyzed data and drew the figures. G.Q.G., T.Z., X.Y. and Z.Z.F. wrote the manuscript; All authors have read and approved the article.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

These authors contributed equally: Zhenzhen Fang, Gang Shen, Yina Wang, Fuyan Hong

Contributor Information

Xia Yang, Email: yangxia@mail.sysu.edu.cn.

Ti Zhou, Email: zhouti2@mail.sysu.edu.cn.

Guoquan Gao, Email: gaogq@mail.sysu.edu.cn.

Supplementary information

The online version contains supplementary material available at 10.1038/s41392-024-01781-9.

References

1.Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–1864. doi: 10.1053/j.gastro.2020.01.052. [DOI] [PubMed] [Google Scholar]
2.Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769–1777. doi: 10.1053/j.gastro.2016.02.066. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Du T, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65:1391–1398. doi: 10.1016/j.metabol.2016.06.006. [DOI] [PubMed] [Google Scholar]
4.Li H, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int. J. Environ. Res. Public Health. 2020;17:1818. doi: 10.3390/ijerph17061818. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Chen YL, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21:212. doi: 10.1186/s12876-021-01782-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109. [DOI] [PubMed] [Google Scholar]
7.Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–1523. doi: 10.1126/science.1204265. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22:11–21. doi: 10.1016/j.cld.2017.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 2016;13:196–205. doi: 10.1038/nrgastro.2016.3. [DOI] [PubMed] [Google Scholar]
10.Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016;65:1038–1048. doi: 10.1016/j.metabol.2015.12.012. [DOI] [PubMed] [Google Scholar]
11.Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. doi: 10.1038/nature05485. [DOI] [PubMed] [Google Scholar]
12.Chai KX, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993;268:24498–24505. doi: 10.1016/S0021-9258(20)80553-5. [DOI] [PubMed] [Google Scholar]
13.Feng J, et al. Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization. Cell Commun. Signal. 2019;17:60. doi: 10.1186/s12964-019-0376-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.El-Asrar MA, Andrawes NG, Ismail EA, Salem SM. Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: relation to carotid intima media thickness. Vasc. Med. 2015;20:509–517. doi: 10.1177/1358863X15591089. [DOI] [PubMed] [Google Scholar]
15.Nowicki GJ, Slusarska B, Polak M, Naylor K, Kocki T. Relationship between serum kallistatin and afamin and anthropometric factors associated with obesity and of being overweight in patients after myocardial infarction and without myocardial infarction. J. Clin. Med. 2021;10:5792. doi: 10.3390/jcm10245792. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.van Diepen JA, et al. PPAR-alpha-dependent regulation of vanin-1 mediates hepatic lipid metabolism. J. Hepatol. 2014;61:366–372. doi: 10.1016/j.jhep.2014.04.013. [DOI] [PubMed] [Google Scholar]
17.Wu JW, et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011;54:122–132. doi: 10.1002/hep.24338. [DOI] [PubMed] [Google Scholar]
18.Guo F, et al. Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice. J. Lipid Res. 2013;54:2109–2120. doi: 10.1194/jlr.M035519. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Ronchetti A, et al. Severe steatohepatitis in a patient with a rare neutral lipid storage disorder due to ABHD5 mutation. J. Hepatol. 2008;49:474–477. doi: 10.1016/j.jhep.2008.05.027. [DOI] [PubMed] [Google Scholar]
20.Wu J, et al. Loss of PDK4 switches the hepatic NF-kappaB/TNF pathway from pro-survival to pro-apoptosis. Hepatology. 2018;68:1111–1124. doi: 10.1002/hep.29902. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57. doi: 10.1016/j.cell.2016.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Roy D, et al. Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor gamma (PPARgamma) during adipocyte differentiation. J. Biol. Chem. 2017;292:14827–14835. doi: 10.1074/jbc.M117.783043. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol. Life Sci. 2018;75:2951–2961. doi: 10.1007/s00018-018-2838-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Salmon M, Gomez D, Greene E, Shankman L, Owens GK. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22alpha promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circ. Res. 2012;111:685–696. doi: 10.1161/CIRCRESAHA.112.269811. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Zhang J, et al. Kallistatin antagonizes Wnt/beta-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol. Cell Biochem. 2013;379:295–301. doi: 10.1007/s11010-013-1654-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Kimura T, Pydi SP, Pham J, Tanaka N. Metabolic functions of G protein-coupled receptors in hepatocytes-potential applications for diabetes and NAFLD. Biomolecules. 2020;10:1445. doi: 10.3390/biom10101445. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Wan M, et al. LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Galpha(s) Sci. Signal. 2011;4:ra15. doi: 10.1126/scisignal.2001464. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Domoto T, et al. Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107:1363–1372. doi: 10.1111/cas.13028. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Liu KJ, et al. Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. J. Cell Physiol. 2011;226:424–433. doi: 10.1002/jcp.22348. [DOI] [PubMed] [Google Scholar]
30.Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat. Rev. Cardiol. 2017;14:401–411. doi: 10.1038/nrcardio.2017.31. [DOI] [PubMed] [Google Scholar]
31.Zhang J, et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci. Rep. 2014;4:5832. doi: 10.1038/srep05832. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Liu YY, Nakatani T, Kogai T, Mody K, Brent GA. Thyroid hormone and COUP-TF1 regulate kallikrein-binding protein (KBP) gene expression. Endocrinology. 2011;152:1143–1153. doi: 10.1210/en.2010-0580. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Yamamoto N, Li QL, Mita S, Morisawa S, Inoue A. Inhibition of thyroid hormone binding to the nuclear receptor by mobilization of free fatty acids. Horm. Metab. Res. 2001;33:131–137. doi: 10.1055/s-2001-14939. [DOI] [PubMed] [Google Scholar]
34.Ikeda T, et al. Effect of diabetes on triiodothyronine and reverse triiodothyronine production in the perfused rat liver and kidney. Diabetes. 1985;34:647–652. doi: 10.2337/diab.34.7.647. [DOI] [PubMed] [Google Scholar]
35.Cheng Z, et al. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm. Sin. B. 2015;5:194–200. doi: 10.1016/j.apsb.2015.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Haemmerle G, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312:734–737. doi: 10.1126/science.1123965. [DOI] [PubMed] [Google Scholar]
37.Brown AL, Mark Brown J. Critical roles for alpha/beta hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:1233–1241. doi: 10.1016/j.bbalip.2017.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Ganguli S, DeLeeuw P, Satapathy SK. A review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepat. Med. 2019;11:159–178. doi: 10.2147/HMER.S188991. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Wang X, et al. Transcription factors ZEB1 and CREB promote the transcription of bovine ABHD5 gene. DNA Cell Biol. 2021;40:219–230. doi: 10.1089/dna.2020.5994. [DOI] [PubMed] [Google Scholar]
40.Wang X, et al. Molecular characterization of ABHD5 gene promoter in intramuscular preadipocytes of Qinchuan cattle: roles of Evi1 and C/EBPalpha. Gene. 2019;690:38–47. doi: 10.1016/j.gene.2018.12.030. [DOI] [PubMed] [Google Scholar]
41.Cakmak E, et al. Steatohepatitis and liver cirrhosis in Chanarin-Dorfman syndrome with a new ABDH5 mutation. Clin. Res. Hepatol. Gastroenterol. 2012;36:e34–e37. doi: 10.1016/j.clinre.2011.12.007. [DOI] [PubMed] [Google Scholar]
42.Schreiber R, et al. Hypophagia and metabolic adaptations in mice with defective ATGL-mediated lipolysis cause resistance to HFD-induced obesity. Proc. Natl Acad. Sci. USA. 2015;112:13850–13855. doi: 10.1073/pnas.1516004112. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Lord CC, et al. Regulation of hepatic triacylglycerol metabolism by CGI-58 does not require ATGL co-activation. Cell Rep. 2016;16:939–949. doi: 10.1016/j.celrep.2016.06.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Brown JM, et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 2010;51:3306–3315. doi: 10.1194/jlr.M010256. [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Shang S, et al. Macrophage ABHD5 suppresses NFkappaB-dependent matrix metalloproteinase expression and cancer metastasis. Cancer Res. 2019;79:5513–5526. doi: 10.1158/0008-5472.CAN-19-1059. [DOI] [PubMed] [Google Scholar]
46.Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005;30:43–52. doi: 10.1016/j.tibs.2004.11.009. [DOI] [PubMed] [Google Scholar]
47.Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008;14:72–81. doi: 10.1016/j.molmed.2007.12.003. [DOI] [PubMed] [Google Scholar]
48.Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008;51:1358–1365. doi: 10.1161/HYPERTENSIONAHA.107.108514. [DOI] [PubMed] [Google Scholar]
49.Li P, et al. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014;142:216–226. doi: 10.1111/imm.12242. [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Li P, et al. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit. Care. 2015;19:200. doi: 10.1186/s13054-015-0919-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Chao J, Bledsoe G, Chao L. Protective role of kallistatin in vascular and organ injury. Hypertension. 2016;68:533–541. doi: 10.1161/HYPERTENSIONAHA.116.07861. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Kopf T, et al. Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. PLoS One. 2014;9:e106849. doi: 10.1371/journal.pone.0106849. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021;15:827–840. doi: 10.5009/gnl20367. [DOI] [PMC free article] [PubMed] [Google Scholar]
54.Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. Rep. 2013;1:57–64. doi: 10.3892/br.2012.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: targets and therapy. Pharmacol. Res. 2021;167:105484. doi: 10.1016/j.phrs.2021.105484. [DOI] [PubMed] [Google Scholar]
56.Oscarsson J, et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J. Clin. Lipidol. 2018;12:1390–1403.e1394. doi: 10.1016/j.jacl.2018.08.003. [DOI] [PubMed] [Google Scholar]
57.Fernandez-Miranda C, et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 2008;40:200–205. doi: 10.1016/j.dld.2007.10.002. [DOI] [PubMed] [Google Scholar]
58.Yaghoubi M, et al. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2017;29:1385–1388. doi: 10.1097/MEG.0000000000000981. [DOI] [PubMed] [Google Scholar]
59.Athyros VG, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 2006;22:873–883. doi: 10.1185/030079906X104696. [DOI] [PubMed] [Google Scholar]
60.El-Haggar SM, Mostafa TM. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. Hepatol. Int. 2015;9:471–479. doi: 10.1007/s12072-015-9633-1. [DOI] [PubMed] [Google Scholar]
61.Liu X, et al. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013;62:4228–4238. doi: 10.2337/db12-1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701. [DOI] [PubMed] [Google Scholar]
63.Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1811–1822.e1814. doi: 10.1053/j.gastro.2016.03.008. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

supplementary figures and tables^{(3.1MB, docx)}

Unmodified gels^{(2.1MB, pdf)}

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

[CR1] 1.Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–1864. doi: 10.1053/j.gastro.2020.01.052. [DOI] [PubMed] [Google Scholar]

[CR2] 2.Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769–1777. doi: 10.1053/j.gastro.2016.02.066. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR3] 3.Du T, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65:1391–1398. doi: 10.1016/j.metabol.2016.06.006. [DOI] [PubMed] [Google Scholar]

[CR4] 4.Li H, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int. J. Environ. Res. Public Health. 2020;17:1818. doi: 10.3390/ijerph17061818. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR5] 5.Chen YL, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21:212. doi: 10.1186/s12876-021-01782-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] 6.Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109. [DOI] [PubMed] [Google Scholar]

[CR7] 7.Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–1523. doi: 10.1126/science.1204265. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22:11–21. doi: 10.1016/j.cld.2017.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR9] 9.Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 2016;13:196–205. doi: 10.1038/nrgastro.2016.3. [DOI] [PubMed] [Google Scholar]

[CR10] 10.Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016;65:1038–1048. doi: 10.1016/j.metabol.2015.12.012. [DOI] [PubMed] [Google Scholar]

[CR11] 11.Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. doi: 10.1038/nature05485. [DOI] [PubMed] [Google Scholar]

[CR12] 12.Chai KX, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993;268:24498–24505. doi: 10.1016/S0021-9258(20)80553-5. [DOI] [PubMed] [Google Scholar]

[CR13] 13.Feng J, et al. Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization. Cell Commun. Signal. 2019;17:60. doi: 10.1186/s12964-019-0376-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR14] 14.El-Asrar MA, Andrawes NG, Ismail EA, Salem SM. Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: relation to carotid intima media thickness. Vasc. Med. 2015;20:509–517. doi: 10.1177/1358863X15591089. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Nowicki GJ, Slusarska B, Polak M, Naylor K, Kocki T. Relationship between serum kallistatin and afamin and anthropometric factors associated with obesity and of being overweight in patients after myocardial infarction and without myocardial infarction. J. Clin. Med. 2021;10:5792. doi: 10.3390/jcm10245792. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR16] 16.van Diepen JA, et al. PPAR-alpha-dependent regulation of vanin-1 mediates hepatic lipid metabolism. J. Hepatol. 2014;61:366–372. doi: 10.1016/j.jhep.2014.04.013. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Wu JW, et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011;54:122–132. doi: 10.1002/hep.24338. [DOI] [PubMed] [Google Scholar]

[CR18] 18.Guo F, et al. Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice. J. Lipid Res. 2013;54:2109–2120. doi: 10.1194/jlr.M035519. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR19] 19.Ronchetti A, et al. Severe steatohepatitis in a patient with a rare neutral lipid storage disorder due to ABHD5 mutation. J. Hepatol. 2008;49:474–477. doi: 10.1016/j.jhep.2008.05.027. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Wu J, et al. Loss of PDK4 switches the hepatic NF-kappaB/TNF pathway from pro-survival to pro-apoptosis. Hepatology. 2018;68:1111–1124. doi: 10.1002/hep.29902. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR21] 21.Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57. doi: 10.1016/j.cell.2016.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR22] 22.Roy D, et al. Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor gamma (PPARgamma) during adipocyte differentiation. J. Biol. Chem. 2017;292:14827–14835. doi: 10.1074/jbc.M117.783043. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR23] 23.Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol. Life Sci. 2018;75:2951–2961. doi: 10.1007/s00018-018-2838-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR24] 24.Salmon M, Gomez D, Greene E, Shankman L, Owens GK. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22alpha promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circ. Res. 2012;111:685–696. doi: 10.1161/CIRCRESAHA.112.269811. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR25] 25.Zhang J, et al. Kallistatin antagonizes Wnt/beta-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol. Cell Biochem. 2013;379:295–301. doi: 10.1007/s11010-013-1654-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR26] 26.Kimura T, Pydi SP, Pham J, Tanaka N. Metabolic functions of G protein-coupled receptors in hepatocytes-potential applications for diabetes and NAFLD. Biomolecules. 2020;10:1445. doi: 10.3390/biom10101445. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR27] 27.Wan M, et al. LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Galpha(s) Sci. Signal. 2011;4:ra15. doi: 10.1126/scisignal.2001464. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR28] 28.Domoto T, et al. Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107:1363–1372. doi: 10.1111/cas.13028. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR29] 29.Liu KJ, et al. Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. J. Cell Physiol. 2011;226:424–433. doi: 10.1002/jcp.22348. [DOI] [PubMed] [Google Scholar]

[CR30] 30.Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat. Rev. Cardiol. 2017;14:401–411. doi: 10.1038/nrcardio.2017.31. [DOI] [PubMed] [Google Scholar]

[CR31] 31.Zhang J, et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci. Rep. 2014;4:5832. doi: 10.1038/srep05832. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR32] 32.Liu YY, Nakatani T, Kogai T, Mody K, Brent GA. Thyroid hormone and COUP-TF1 regulate kallikrein-binding protein (KBP) gene expression. Endocrinology. 2011;152:1143–1153. doi: 10.1210/en.2010-0580. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR33] 33.Yamamoto N, Li QL, Mita S, Morisawa S, Inoue A. Inhibition of thyroid hormone binding to the nuclear receptor by mobilization of free fatty acids. Horm. Metab. Res. 2001;33:131–137. doi: 10.1055/s-2001-14939. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Ikeda T, et al. Effect of diabetes on triiodothyronine and reverse triiodothyronine production in the perfused rat liver and kidney. Diabetes. 1985;34:647–652. doi: 10.2337/diab.34.7.647. [DOI] [PubMed] [Google Scholar]

[CR35] 35.Cheng Z, et al. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm. Sin. B. 2015;5:194–200. doi: 10.1016/j.apsb.2015.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR36] 36.Haemmerle G, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312:734–737. doi: 10.1126/science.1123965. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Brown AL, Mark Brown J. Critical roles for alpha/beta hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:1233–1241. doi: 10.1016/j.bbalip.2017.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR38] 38.Ganguli S, DeLeeuw P, Satapathy SK. A review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepat. Med. 2019;11:159–178. doi: 10.2147/HMER.S188991. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR39] 39.Wang X, et al. Transcription factors ZEB1 and CREB promote the transcription of bovine ABHD5 gene. DNA Cell Biol. 2021;40:219–230. doi: 10.1089/dna.2020.5994. [DOI] [PubMed] [Google Scholar]

[CR40] 40.Wang X, et al. Molecular characterization of ABHD5 gene promoter in intramuscular preadipocytes of Qinchuan cattle: roles of Evi1 and C/EBPalpha. Gene. 2019;690:38–47. doi: 10.1016/j.gene.2018.12.030. [DOI] [PubMed] [Google Scholar]

[CR41] 41.Cakmak E, et al. Steatohepatitis and liver cirrhosis in Chanarin-Dorfman syndrome with a new ABDH5 mutation. Clin. Res. Hepatol. Gastroenterol. 2012;36:e34–e37. doi: 10.1016/j.clinre.2011.12.007. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Schreiber R, et al. Hypophagia and metabolic adaptations in mice with defective ATGL-mediated lipolysis cause resistance to HFD-induced obesity. Proc. Natl Acad. Sci. USA. 2015;112:13850–13855. doi: 10.1073/pnas.1516004112. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR43] 43.Lord CC, et al. Regulation of hepatic triacylglycerol metabolism by CGI-58 does not require ATGL co-activation. Cell Rep. 2016;16:939–949. doi: 10.1016/j.celrep.2016.06.049. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR44] 44.Brown JM, et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 2010;51:3306–3315. doi: 10.1194/jlr.M010256. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR45] 45.Shang S, et al. Macrophage ABHD5 suppresses NFkappaB-dependent matrix metalloproteinase expression and cancer metastasis. Cancer Res. 2019;79:5513–5526. doi: 10.1158/0008-5472.CAN-19-1059. [DOI] [PubMed] [Google Scholar]

[CR46] 46.Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005;30:43–52. doi: 10.1016/j.tibs.2004.11.009. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008;14:72–81. doi: 10.1016/j.molmed.2007.12.003. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008;51:1358–1365. doi: 10.1161/HYPERTENSIONAHA.107.108514. [DOI] [PubMed] [Google Scholar]

[CR49] 49.Li P, et al. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014;142:216–226. doi: 10.1111/imm.12242. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR50] 50.Li P, et al. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit. Care. 2015;19:200. doi: 10.1186/s13054-015-0919-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR51] 51.Chao J, Bledsoe G, Chao L. Protective role of kallistatin in vascular and organ injury. Hypertension. 2016;68:533–541. doi: 10.1161/HYPERTENSIONAHA.116.07861. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR52] 52.Kopf T, et al. Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. PLoS One. 2014;9:e106849. doi: 10.1371/journal.pone.0106849. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR53] 53.Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021;15:827–840. doi: 10.5009/gnl20367. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR54] 54.Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. Rep. 2013;1:57–64. doi: 10.3892/br.2012.18. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR55] 55.Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: targets and therapy. Pharmacol. Res. 2021;167:105484. doi: 10.1016/j.phrs.2021.105484. [DOI] [PubMed] [Google Scholar]

[CR56] 56.Oscarsson J, et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J. Clin. Lipidol. 2018;12:1390–1403.e1394. doi: 10.1016/j.jacl.2018.08.003. [DOI] [PubMed] [Google Scholar]

[CR57] 57.Fernandez-Miranda C, et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 2008;40:200–205. doi: 10.1016/j.dld.2007.10.002. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Yaghoubi M, et al. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2017;29:1385–1388. doi: 10.1097/MEG.0000000000000981. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Athyros VG, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 2006;22:873–883. doi: 10.1185/030079906X104696. [DOI] [PubMed] [Google Scholar]

[CR60] 60.El-Haggar SM, Mostafa TM. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. Hepatol. Int. 2015;9:471–479. doi: 10.1007/s12072-015-9633-1. [DOI] [PubMed] [Google Scholar]

[CR61] 61.Liu X, et al. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013;62:4228–4238. doi: 10.2337/db12-1710. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR62] 62.Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701. [DOI] [PubMed] [Google Scholar]

[CR63] 63.Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1811–1822.e1814. doi: 10.1053/j.gastro.2016.03.008. [DOI] [PubMed] [Google Scholar]

PERMALINK

Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease

Zhenzhen Fang

Gang Shen

Yina Wang

Fuyan Hong

Xiumei Tang

Yongcheng Zeng

Ting Zhang

Huanyi Liu

Yanmei Li

Jinhong Wang

Jing Zhang

Anton Gao

Weiwei Qi

Xia Yang

Ti Zhou

Guoquan Gao

Abstract

Introduction

Results

The level of KAL is increased in HLP and NAFLD patients and positively correlated with TG

Fig. 1.

Elevated KAL induces hepatic steatosis and NASH in chow-diet mice and aggravates hepatic steatosis to NASH in HFD mice

Fig. 2.

Knockout of KAL ameliorates hepatic steatosis and inflammation in NAFLD rats

Fig. 3.

KAL causes hepatic steatosis by down-regulating both CGI-58 and ATGL, and inflammation mainly by CGI-58

Fig. 4.

KAL induces nuclear translocation of NF-κB p65 by reducing its binding to CGI-58 in hepatocytes

Fig. 5.

KAL down-regulates ATGL and CGI-58 by inhibiting PPARγ or inducing KLF4, respectively

Fig. 6.

KAL regulates KLF4 and PPARγ by LRP6/Gαs/PKA/GSK3β signals

Fig. 7.

High FFA reverses the downregulation of KAL induced by T3, and fenofibrate down-regulates KAL in hepatocytes

Fig. 8.

Discussion

Fig. 9.

Materials and methods

Ethics statements

Experimental design of human subjects

Experimental design of animals

Cell-culture experiments

Histological analyses

Enzyme-linked immuno sorbent assay (ELISA) specific for KAL

Immunoprecipitation, isolation of nuclear fractions and western blot

Plasmids, siRNA, and transfection

RNA isolation and real-time quantitative polymerase chain reaction (RT-qPCR)

Luciferase reporter assay

Statistical analysis

Supplementary information

Acknowledgements

Author contributions

Data availability

Competing interests

Footnotes

Contributor Information

Supplementary information

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases